Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

SI-BONE stock price, quote, forecast and news

SIBN
US8257041090
A2N7LY

Price

15.58
Today +/-
+0
Today %
+0 %
P

SI-BONE Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into SI-BONE, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by SI-BONE from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects SI-BONE’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of SI-BONE. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into SI-BONE’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing SI-BONE’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on SI-BONE’s growth potential.

SI-BONE Revenue, EBIT and net profit per share

DateSI-BONE RevenueSI-BONE EBITSI-BONE Net Income
2026e231.28 M undefined-23.56 M undefined-21.22 M undefined
2025e195.46 M undefined-35.86 M undefined-33.05 M undefined
2024e168.35 M undefined-42.98 M undefined-40.04 M undefined
2023138.89 M undefined-46.93 M undefined-43.34 M undefined
2022106.4 M undefined-59.6 M undefined-61.3 M undefined
202190.2 M undefined-51.7 M undefined-56.6 M undefined
202073.4 M undefined-38.6 M undefined-43.7 M undefined
201967.3 M undefined-36 M undefined-38.4 M undefined
201855.4 M undefined-12 M undefined-17.5 M undefined
201748 M undefined-17.4 M undefined-23 M undefined
201642.1 M undefined-17.6 M undefined-20.6 M undefined
201541.2 M undefined-26.4 M undefined-28.2 M undefined
201440.1 M undefined-26.3 M undefined-27.8 M undefined
201349 M undefined-5.3 M undefined-6.2 M undefined

SI-BONE Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201320142015201620172018201920202021202220232024e2025e2026e
494041424855677390106138168195231
--18.372.502.4414.2914.5821.828.9623.2917.7830.1921.7416.0718.46
89.8082.5085.3785.7187.5090.9189.5587.6787.7884.9178.99---
44333536425060647990109000
-5-26-26-17-17-12-36-38-51-59-46-42-35-23
-10.20-65.00-63.41-40.48-35.42-21.82-53.73-52.05-56.67-55.66-33.33-25.00-17.95-9.96
-6-27-28-20-23-17-38-43-56-61-43-40-33-21
-350.003.70-28.5715.00-26.09123.5313.1630.238.93-29.51-6.98-17.50-36.36
21.821.821.821.821.8824.729.133.134.238.43000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The SI-BONE Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the SI-BONE is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of SI-BONE provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand SI-BONE's financial health and stability.

Assets

SI-BONE's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that SI-BONE must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of SI-BONE after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into SI-BONE's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20132014201520162017201820192020202120222023
-6-27-28-20-23-17-38-43-56-61-43
00011001235
00000000000
40-100-10-2-5-7-4
0224551326374648
00004544323
00000000000
0-26-26-16-17-14-31-30-39-41-18
0-2-2000-2-2-6-9-7
0-2-200-9713-6251-2-59
00000-9615-60576-51
00000000000
10410438000-600
0332220511731374290
8383124121153136-1290
-1.00--1.00--31.00-1.00--1.00---
00000000000
6927-52-14439-4212
-1.31-29.2-28.96-17.19-18.01-15.46-34.08-33.22-45.92-51.17-26.51
00000000000

SI-BONE stock margins

The SI-BONE margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SI-BONE. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SI-BONE.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the SI-BONE's sales revenue. A higher gross margin percentage indicates that the SI-BONE retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the SI-BONE's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the SI-BONE's total revenue generated. When comparing the revenue margin year over year, investors can gauge the SI-BONE's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the SI-BONE. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the SI-BONE's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

SI-BONE Margin History

SI-BONE Gross marginSI-BONE Profit marginSI-BONE EBIT marginSI-BONE Profit margin
2026e78.78 %-10.19 %-9.18 %
2025e78.78 %-18.34 %-16.91 %
2024e78.78 %-25.53 %-23.78 %
202378.78 %-33.79 %-31.2 %
202285.24 %-56.02 %-57.61 %
202188.36 %-57.32 %-62.75 %
202087.87 %-52.59 %-59.54 %
201989.9 %-53.49 %-57.06 %
201891.16 %-21.66 %-31.59 %
201789.38 %-36.25 %-47.92 %
201687.65 %-41.81 %-48.93 %
201586.89 %-64.08 %-68.45 %
201483.79 %-65.59 %-69.33 %
201391.22 %-10.82 %-12.65 %

SI-BONE Stock Sales Revenue, EBIT, Earnings per Share

The SI-BONE earnings per share therefore indicates how much revenue SI-BONE has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue SI-BONE earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates SI-BONE's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of SI-BONE’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating SI-BONE's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

SI-BONE Revenue, EBIT and net profit per share

DateSI-BONE Sales per ShareSI-BONE EBIT per shareSI-BONE Earnings per Share
2026e5.61 undefined0 undefined-0.52 undefined
2025e4.74 undefined0 undefined-0.8 undefined
2024e4.09 undefined0 undefined-0.97 undefined
20233.61 undefined-1.22 undefined-1.13 undefined
20223.11 undefined-1.74 undefined-1.79 undefined
20212.73 undefined-1.56 undefined-1.71 undefined
20202.52 undefined-1.33 undefined-1.5 undefined
20192.72 undefined-1.46 undefined-1.55 undefined
20186.93 undefined-1.5 undefined-2.19 undefined
20172.2 undefined-0.8 undefined-1.06 undefined
20161.93 undefined-0.81 undefined-0.94 undefined
20151.89 undefined-1.21 undefined-1.29 undefined
20141.84 undefined-1.21 undefined-1.28 undefined
20132.25 undefined-0.24 undefined-0.28 undefined

SI-BONE business model

SI-BONE Inc. is an innovative medical technology company based in Santa Clara, California. It was founded in 2008 by a group of orthopedic surgeons, engineers, and entrepreneurs who aimed to improve the treatment of lower back pain. The company is now globally recognized and specializes in the development and marketing of implants for the treatment of pain and discomfort in the pelvic and back areas. SI-BONE focuses on the treatment of pain and discomfort in the pelvic and back areas, offering a range of products for this purpose. The company's main focus is on the development of innovative implants that can be used minimally invasively, with the goal of providing patients with quick recovery and improved quality of life. The flagship product of SI-BONE is the iFuse implant. This implant is used in patients with chronic lower back pain caused by instability of the spine or pelvis. The iFuse implant stabilizes the pelvis and thereby reduces the pain originating from the unstable joint region. The iFuse implant has been FDA approved and is now available in over 40 countries worldwide. In addition to the iFuse implant, SI-BONE also offers a variety of other products tailored to the needs of physicians and patients. These include implantable instruments and consumables such as bone screws or arthroscopy needles. SI-BONE is a publicly traded company listed on NASDAQ under the ticker symbol "SIBN." The company's business model is based on providing innovative products to physicians and hospitals that optimize the treatment of back pain. To achieve this, SI-BONE works closely with leading industry professionals to enable optimal treatment of back pain. SI-BONE has established itself as a strong, innovative company specializing in minimally invasive implants in the field of pain therapy. Through close collaboration with physicians and specialists and investment in research and development of cutting-edge technologies, SI-BONE aims to continue growing and achieve a leading position in the field of pain therapy. SI-BONE is one of the most popular companies on Eulerpool.com.

SI-BONE SWOT Analysis

Strengths

SI-BONE Inc possesses advanced proprietary technology, allowing it to develop innovative medical solutions for patients suffering from various spinal disorders.

SI-BONE Inc has gained a strong reputation within the healthcare industry for its effective diagnostic and treatment solutions, resulting in increased trust from healthcare professionals and patients.

SI-BONE Inc has a substantial portfolio of intellectual property rights, including patents and trademarks, providing a competitive advantage and protecting its innovative technologies.

Weaknesses

SI-BONE Inc heavily relies on its primary product offerings, potentially exposing the company to market fluctuations and limited revenue streams.

Compared to some major competitors, SI-BONE Inc has a relatively smaller market presence, which may limit its ability to reach a wider customer base and compete for market share.

SI-BONE Inc's pricing structure may be perceived as higher compared to some alternatives in the market, potentially leading to pricing sensitivity among cost-conscious customers.

Opportunities

SI-BONE Inc can explore opportunities to expand its reach into untapped geographical markets, allowing the company to target a wider customer base and increase its revenue potential.

By continuously investing in research and development, SI-BONE Inc can introduce new products or enhancements to its existing product line, catering to evolving customer needs and expanding its market share.

SI-BONE Inc can establish strategic partnerships with other companies or healthcare organizations to leverage complementary expertise and resources, fueling growth and market penetration.

Threats

SI-BONE Inc operates in a highly competitive industry, facing competition from both established companies and emerging startups, which could impact its market share and profitability.

The medical industry is subject to stringent regulations and compliance requirements. SI-BONE Inc may face challenges related to regulatory approvals, affecting its ability to commercialize products in a timely manner.

Fluctuations in the global economy, changes in healthcare policies, or economic downturns can influence customer spending patterns, potentially impacting SI-BONE Inc's revenues and profitability.

SI-BONE historical P/E ratio, EBIT, and P/S ratio.

SI-BONE shares outstanding

The number of shares was SI-BONE in 2023 — This indicates how many shares 38.427 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue SI-BONE earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates SI-BONE's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of SI-BONE’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating SI-BONE's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for SI-BONE.

SI-BONE latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-0.32 -0.27  (14.45 %)2024 Q1
12/31/2023-0.29 -0.27  (5.33 %)2023 Q4
9/30/2023-0.35 -0.25  (28.49 %)2023 Q3
6/30/2023-0.4 -0.3  (25.85 %)2023 Q2
3/31/2023-0.42 -0.32  (23.41 %)2023 Q1
12/31/2022-0.41 -0.32  (21.47 %)2022 Q4
9/30/2022-0.48 -0.41  (15.08 %)2022 Q3
6/30/2022-0.5 -0.54  (-8.02 %)2022 Q2
3/31/2022-0.44 -0.52  (-19.51 %)2022 Q1
12/31/2021-0.4 -0.43  (-8.7 %)2021 Q4
1
2
3

Eulerpool ESG Scorecard© for the SI-BONE stock

Eulerpool World ESG Rating (EESG©)

37/ 100

🌱 Environment

5

👫 Social

63

🏛️ Governance

42

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
✅
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees45
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

SI-BONE list of shareholders

%
Name
Stocks
Change
Date
7.64 % BlackRock Institutional Trust Company, N.A.3,147,596482,96212/31/2023
6.18 % First Light Asset Management, LLC2,547,39223,29912/31/2023
5.86 % The Vanguard Group, Inc.2,412,317111,31512/31/2023
5.56 % OrbiMed Advisors, LLC2,292,531012/31/2023
3.39 % Next Century Growth Investors, LLC1,398,41326,33912/31/2023
3.12 % Granahan Investment Management, LLC1,286,450150,21712/31/2023
2.94 % Millennium Management LLC1,210,324-777,26012/31/2023
2.91 % Champlain Investment Partners, LLC1,197,537765,29012/31/2023
2.86 % American Century Investment Management, Inc.1,179,5241,179,52412/31/2023
2.36 % State Street Global Advisors (US)971,317-38,15512/31/2023
1
2
3
4
5
...
10

SI-BONE Executives and Management Board

Ms. Laura Francis56
SI-BONE Chief Executive Officer, Director (since 2015)
Compensation 4.89 M
Mr. Anthony Recupero64
SI-BONE President - Commercial Operations
Compensation 2.36 M
Mr. Anshul Maheshwari43
SI-BONE Chief Financial Officer
Compensation 2.13 M
Mr. Jeffrey Dunn68
SI-BONE Executive Chairman of the Board (since 2008)
Compensation 1.16 M
Dr. John Freund69
SI-BONE Independent Director
Compensation 415,797
1
2
3

Most common questions regarding SI-BONE

What values and corporate philosophy does SI-BONE represent?

SI-BONE Inc represents a commitment to improving patient lives through innovative medical solutions. Their corporate philosophy revolves around providing minimally invasive technologies for the diagnosis, treatment, and management of musculoskeletal disorders. The company actively focuses on advancing the field of sacroiliac joint dysfunction (SIJD) treatment with their FDA-cleared iFuse Implant System, offering a comprehensive solution for patients suffering from SIJD. SI-BONE Inc values patient-centric care, clinical research, collaboration with healthcare professionals, and continuous innovation to enhance patient outcomes. With their dedication to addressing unmet medical needs and improving quality of life, SI-BONE Inc has emerged as a trusted leader in the field of musculoskeletal healthcare.

In which countries and regions is SI-BONE primarily present?

SI-BONE Inc is primarily present in the United States and Europe.

What significant milestones has the company SI-BONE achieved?

SI-BONE Inc has achieved several significant milestones in their history. One noteworthy accomplishment is the FDA clearance of their iFuse Implant System, a minimally invasive surgical solution for sacroiliac joint fusion. This clearance allowed SI-BONE Inc to offer their innovative treatment to patients suffering from SI joint dysfunction. Additionally, the company went public in 2018, marking another milestone in their growth. SI-BONE Inc's dedication to research and development has led to advancements in medical technology and improved patient outcomes. They continue to make strides in the field of SI joint fusion and are committed to providing effective solutions for patients.

What is the history and background of the company SI-BONE?

SI-BONE Inc is a leading medical device company specializing in minimally invasive solutions for the treatment of sacroiliac (SI) joint dysfunction. Founded in 2008, SI-BONE has emerged as a pioneer in this field, revolutionizing the way SI joint pain is diagnosed and treated. The company's flagship product is the iFuse Implant System, which provides a durable and minimally invasive option for patients suffering from SI joint dysfunction. Backed by extensive clinical research and a commitment to innovation, SI-BONE Inc has quickly gained recognition as a trusted provider of SI joint solutions, improving the quality of life for countless patients worldwide.

Who are the main competitors of SI-BONE in the market?

The main competitors of SI-BONE Inc in the market are Zimmer Biomet Holdings Inc, Medtronic PLC, and NuVasive Inc.

In which industries is SI-BONE primarily active?

SI-BONE Inc is primarily active in the healthcare industry, specifically specializing in the development and commercialization of innovative medical devices for patients suffering from musculoskeletal disorders. The company focuses on providing minimally invasive, cutting-edge solutions for the diagnosis and treatment of conditions related to the sacroiliac joint. With their groundbreaking technology and dedication to improving patient outcomes, SI-BONE Inc has positioned itself as a leader in the healthcare sector, offering effective solutions for individuals in need of long-term relief from debilitating pain and discomfort.

What is the business model of SI-BONE?

The business model of SI-BONE Inc is focused on developing minimally invasive surgical solutions for patients suffering from sacroiliac (SI) joint disorders. The company specializes in the design and manufacturing of medical devices, including the iFuse Implant System. SI-BONE's innovative approach involves utilizing advanced technology and expertise to address the biomechanical causes of SI joint dysfunction. By providing effective treatment options, SI-BONE aims to improve patients' quality of life and restore their mobility. As a leader in the field, SI-BONE Inc continues to prioritize research, innovation, and collaboration with healthcare professionals in order to offer cutting-edge solutions for SI joint disorders.

What is the P/E ratio of SI-BONE 2024?

The SI-BONE P/E ratio is -14.95.

What is the P/S ratio of SI-BONE 2024?

The SI-BONE P/S ratio is 3.56.

What is the AlleAktien quality score of SI-BONE?

The AlleAktien quality score for SI-BONE is 7/10.

What is the revenue of SI-BONE 2024?

The expected SI-BONE revenue is 168.35 M USD.

How high is the profit of SI-BONE 2024?

The expected SI-BONE profit is -40.04 M USD.

What is the business model of SI-BONE

SI-BONE Inc is a medical company specialized in the development and marketing of innovative medical products in the field of spinal surgery. The company was founded in 2008 and is headquartered in Santa Clara, California. SI-BONE Inc specializes in the treatment of degenerative spinal diseases, particularly chronic lower back pain caused by Sacroiliac Joint Dysfunction. This condition affects millions of people worldwide and can lead to significant limitations in daily life. The business model of SI-BONE Inc is based on the development and marketing of innovative medical products aimed at improving the effectiveness and efficiency of Sacroiliac Joint Fusion (SI Fusion). Through the development of new technologies and applications, the company has introduced numerous products that support both minimally invasive and traditional surgical procedures. The flagship product of SI-BONE Inc is the iFuse Implant System, which is considered the only approved method for Sacroiliac Joint Fusion. The iFuse Implant is a small, triangular implant that is inserted into the SI Joint and provides permanent fixation. The implant is made of titanium, known for its strength and biocompatibility. In addition to the iFuse Implant System, SI-BONE Inc also offers a variety of training programs and support services for surgeons and medical professionals. The company has established a comprehensive network of clinics and medical centers to facilitate access to its products and services and raise awareness of the effectiveness of Sacroiliac Joint Fusion. SI-BONE Inc has also built a strong presence in the global market and works closely with international distributors to distribute its products worldwide. The company has branches in Europe, the Middle East, Africa, Asia, and Latin America to meet the needs of its global customers. The business model of SI-BONE Inc benefits both patients and surgeons and medical professionals. By providing innovative medical products and support services, the company contributes to improving patients' quality of life and avoiding potentially irreversible damage to the spine.

What is the SI-BONE dividend?

SI-BONE pays a dividend of 0 USD distributed over payouts per year.

How often does SI-BONE pay dividends?

The dividend cannot currently be calculated for SI-BONE or the company does not pay out a dividend.

What is the SI-BONE ISIN?

The ISIN of SI-BONE is US8257041090.

What is the SI-BONE WKN?

The WKN of SI-BONE is A2N7LY.

What is the SI-BONE ticker?

The ticker of SI-BONE is SIBN.

How much dividend does SI-BONE pay?

Over the past 12 months, SI-BONE paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SI-BONE is expected to pay a dividend of 0 USD.

What is the dividend yield of SI-BONE?

The current dividend yield of SI-BONE is .

When does SI-BONE pay dividends?

SI-BONE pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SI-BONE?

SI-BONE paid dividends every year for the past 0 years.

What is the dividend of SI-BONE?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is SI-BONE located?

SI-BONE is assigned to the 'Health' sector.

Wann musste ich die Aktien von SI-BONE kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SI-BONE from 7/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/16/2024.

When did SI-BONE pay the last dividend?

The last dividend was paid out on 7/16/2024.

What was the dividend of SI-BONE in the year 2023?

In the year 2023, SI-BONE distributed 0 USD as dividends.

In which currency does SI-BONE pay out the dividend?

The dividends of SI-BONE are distributed in USD.

All fundamentals about SI-BONE

Our stock analysis for SI-BONE Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SI-BONE Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.